Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Mechanism of Action — HPG Axis vs Melanocortin Pathway

Kisspeptin's mechanism starts at the hypothalamus. It binds to GPR54 (KISS1R), a G-protein coupled receptor expressed on GnRH neurons. That binding event triggers GnRH secretion into the hypophyseal portal system, which travels to the anterior pituitary and st

This comparison does not assign a generated winner or score.

  • Kisspeptin's mechanism starts at the hypothalamus. It binds to GPR54 (KISS1R), a G-protein coupled receptor expressed on GnRH neurons. That binding event triggers GnRH secretion into the hypophyseal portal system, which travels to the anterior pituitary and stimulates gonadotrophs to release LH and FSH. In men, LH stimulates Leydig cells to produce testosterone; FSH stimulates Sertoli cells to support spermatogenesis. In women, LH and FSH regulate ovarian follicle development and estradiol production. The sexual arousal effect of kisspeptin is downstream of this entire hormonal cascade. It requires functional GnRH neurons, a responsive pituitary, and gonadal tissue capable of hormone synthesis.
  • PT-141 skips all of that. It's a cyclic heptapeptide analog of alpha-MSH (alpha-melanocyte-stimulating hormone) that directly activates melanocortin receptors MC3R and MC4R in the paraventricular nucleus of the hypothalamus and other limbic regions. These receptors are not part of the HPG axis. They're involved in appetite regulation, energy homeostasis, and sexual motivation. PT-141's arousal effect is mediated by increased dopaminergic and oxytocin neurotransmission in areas of the brain that regulate desire and genital response. It works within 45–90 minutes of subcutaneous injection and doesn't require intact gonadal function. A study published in The Journal of Sexual Medicine demonstrated that bremelanotide (PT-141) produced statistically significant increases in sexual desire and satisfying sexual events in premenopausal women with hypoactive sexual desire disorder. Without altering circulating estradiol, testosterone, or prolactin levels.
  • The practical implication: kisspeptin is appropriate for individuals with functional but suppressed HPG axis activity (stress-induced hypogonadism, hypothalamic amenorrhea, GnRH deficiency). PT-141 is appropriate for CNS-mediated sexual dysfunction regardless of hormonal status.
More references

Related material